OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	55
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	25
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	23
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	19
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	17
Learning pharmacometric covariate model structures with symbolic regression networks	17
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	13
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	13
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	12
Current practices for QSP model assessment: an IQ consortium survey	12
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	11
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	11
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	11
ADPO: automatic-differentiation-assisted parametric optimization	11
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	10
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	10
Imputation of missing clock times – application to procalcitonin concentration time course after birth	10
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	10
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	9
Informatics for toxicokinetics	9
Training the next generation of pharmacometric modelers: a multisector perspective	9
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	9
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	8

Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	8
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	8
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Scoping review of the role of pharmacometrics in model-informed drug development	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
Thanks to our Reviewers of 2022!	7
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	6
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	6
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	5
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	5
Application of machine learning based methods in exposure–response analysis	5
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	5
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	5
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	5
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	5
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	5
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	4
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	4
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	4
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	4
JPKPD October Special Issue - Commentary	4
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	4
Computing optimal drug dosing with OptiDose: implementation in NONMEM	4
In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	3
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	3
Editor’s note on the themed issue: integration of machine learning and quantitative systems pharmacology	3
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	3
Generation and application of avatars in pharmacometric modelling	3
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin	3
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	3
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	3
External control arms for rare diseases: building a body of supporting evidence	3
Thanks to our reviewers 2021!	3
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	3
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	3

Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	3
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	3
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	3
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	3
How drug onset rate and duration of action affect drug forgiveness	3
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	3
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	3
Should patients skip late doses of medication? A pharmacokinetic perspective	3
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	3
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	3
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	3
Towards a comprehensive assessment of QSP models: what would it take?	2
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	2
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	2
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	2
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	2
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	2
An industry perspective on current QSP trends in drug development	2
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	2
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	2
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	2
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	2
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	2
Advancing drug development with “Fit-for-Purpose” modeling informed approaches	1
Recommendations for a standardized publication protocol for a QSP model	1
Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics	1
Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modeling	1
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approac	1
Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics	1
Leveraging large language models to compare perspectives on integrating QSP and AI/ML	1
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	1
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	1
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	1
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	1
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	1
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis	1
Generation of realistic virtual adult populations using a model-based copula approach	1
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	1
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	1
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	1
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins	1
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics	1
Pharmacometrics education for all by overcoming language barriers to enhance global collaboration	1
A review of the physiological effects of microgravity and innovative formulation for space travelers	1
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	1
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	1
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach	1
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	1
A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction	1
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model	1
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	1
Pharmacokinetic comparability between two populations using nonlinear mixed effect models: a Monte Carlo study	1
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	1
Dos and don’ts for concentration - QTc analysis as primary analysis for assay sensitivity assessment	1
Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washout	1
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	1
Correction: External control arms for rare diseases: building a body of supporting evidence	1